Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Adriano Venditti, Robert Peter Gale, Francesco Buccisano, Gert Ossenkoppele

Research output: Contribution to journalReview articleAcademicpeer-review

14 Citations (Scopus)
Original languageEnglish
Pages (from-to)963-965
Number of pages3
JournalLeukemia
Volume34
Issue number4
DOIs
Publication statusPublished - 1 Apr 2020

Cite this